Improved Method for the Determination of Phospholipase A2 Catalytic Activity Concentration in Human Serum and Ascites by Schädlich, H. R. et al.
Schädlich et al.: Determination of phospholipase A2 505
J. Clin. Chem. Clin. Biochem.
Vol. 25, 1987, pp. 505-509
© 1987 Walter de Gruyter & Co.
Berlin · New York
Improved Method for the Determination of Phospholipase A2
Catalytic Activity Concentration in Human Serum and Ascites
By H. R. Schädlich, M. Büchler and H. G. Beger
Abteilung für Allgemeine Chirurgie (Ärztlicher Direktor: Prof. Dr. H. G. Beger), Universität Ulm
(Received October 24, 1986/May 21, 1987)
Summary: An improved radiochemical rnethod is presented for the selective determination of phospholipase
A2 activity in human serum and ascites, using only commercially available reagents. The method can be
applied to large quantities of samples. As Substrate we used l,2-dipalmitoyl-sn-glycero(3)phosphoiylcholine
and phosphatidylcholine containing tritiated palmitic acid in position 2 (l-palmitoyl,2-[9,10-3H]palmitoyl-sn-
glycero(3)phosphorylcholine). The liberated fatty acids are extracted and radioactivity is detected in a liquid
scintillation spectrometer.
A preliminary reference ränge of human serum samples was established ranging up to 1.0 U/l. In sera of
patients with acute pancreatitis we found activities up to 20 U/l. The correlation of phospholipase A2 activity
with that of other enzymes and with the severity and complications of acute pancreatitis was investigated.
A possible relationship between phospholipase A2 activities and pulmonary complications is discussed.
Introduction
The severe course of acute pancreatitis is called necro-
tizing pancreatitis, derived from the development of
the necrosis of the gland itself and of the surrounding
tissues. This can lead to shock and multiple ofgan
failüre via the liberation of vasoactive substances and
toxins (1), resulting in a high mortality (2).
Recently, it was proposed that phospholipase A2
(E. C. 3.1.1.4) is the mäin ageüt among the pancreatic
enzymes, leading to local necrosis äs well äs to acute
lung failüre, due to its destructive action on biomem-
branes (3).
Phospholipase A activity is elevated in the sera of
patients with acute pancreatitis (4). In contrast to the
pancreatic enzymes isoamylase, lipase and trypsin (5),
an elevatiori of the phospholipase A activity seems
to be connected with a more severe and more compli-
cated course of the disease (6, 7). These methods,
however, do not distinguish between phospholipase
AI, phospholipase Ai-like and phospholipase A2 ac-
tivity.
In this study, a practicable radiochemical assay for
the selective determination of phospholipase A2 is
presented, which is based on the procedure of Shakir
(8), using only commercially available reagents. It is
applied to patients morphologically well defined by
computed tomography and/or intraoperative findings
(9).
Materials and Methods
Reagents and Instruments
Reagents for the phospholipase A2 assay
l,2-dipalmitoyl-sn-giycero(3)phosphorylcholine, (substrate) re-
ferred to hereafter äs phosphatidylcholine (Serva, Heidelberg,
FRG); 2-[9,10-3H]palmitoyl, l-palmitoyl-sn-glycero(3)phos-
phorylcholine and [l-,I4C]palmitie acid (NEN, Dreieich, FRG);
sodium deoxycholate (Fluka, Neu-Ulm, FRG); purified phos-
pholipase A2 from bog pancreas (Boehringer, Mannheim,
FRG); 2,5-diphenyloxazole (PPO) (Zinsser, Frankfurt, FRG);
2,2'-/?-phenylenebis(5-phenyloxazole) (POPOP) and all other
reagents (Merck, Darmstadt, FRG).
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Instruments
Multipette (Eppendorf, Hamburg, FRG); dispenser (Boehringer,
Mannheim, FRG); membrane pump (Braun, Melsungen, FRG)
for the silicic acid///-heptane Suspension, Liquid Scintillation
Spectrometer LS 1801 (Beckman, Dreieich, FRG).
Pancreas isoamylase was measured according to 1. c. (10), using
the Phadebas Isoamylase lest kit (Pharmacia, Uppsala,
Sweden). Immunoreactive pancreatic lipase was measured using
Enzygnost Lipase (11) (Behring, Frankfurt, FRG).
Samples
Serum and ascites of clinically well evaluated patients with
acute pancreatitis were stored deep frozen up to 4 months until
analysis. The samples were centrifuged after thawing to remove
particles. The presence of pancreatitis was ascertained from
clinical, laboratory and morphological findings.
Method
A 12 mmol/1 solution of phosphatidylcholine in Chloroform/
methanol (2 vol + l vol) was prepared. Tracer was added untü
0.05 ml of this solution contained 20000 counts/min. This stock
solution was stable for several weeks at —28 °C. An aqueous
20 mmol/1 glycine bufTer containing 6 mmol/1 sodium deoxy-
cholate was adjusted to pH 8.0 using l mol/1 NaOH. To prepare
a Substrate solution, the stock solution was dried in a water
bath at 40 °C under a stream of nitrogen, and dissolved again
in the double volume of buffer to attain a Substrate conceütra-
tion of 6 mmol/1. It was mixed well, heated for one minute to
60 °C and cooled down to room temperature. To each 10 ml
of this mixture 0.1 ml of a 0.2 mol/l aqueous CaCl2 solution
was added to obtain a clear solution. This Substrate solution
was prepared afresh for each assay procedure.
In each experiment three 0.02 ml aliquots of serum or ascites
samples were pipetted into PPN (polypropylene) vials. Purified
hog pancreas phospholipase A2, diluted l: 250 000 (vol/vol) in
an aqueous solution of bovine serum albumin (60 g/l) and
NaCJ (9 g/l) äs a control sample and the same bovine serum
albumin/NaCl solution äs a blank sample, were pipetted into
PPN vials in triplicates. To each vial 0.1 ml Substrate solution,
containing 600 nmol phosphatidylcholine, were added. To
determine the total radioactivity of the labelled phosphatidyl-
choline, two 0.1 ml aliquots of the Substrate solution were
pipetted into scintillation vials and stored at room temperature
until liquid scintillation counting. After incubation for 180
minutes in a water bath at 40 °C the reaction was stopped by
adding 0.1 ml aliquots of Dole's reagent (12) (isopropanol/ -
heptane/sulphuric acid (l mol/1) = 4 vol 4- l vol -f 0.025 vol).
All subsequent Steps were performed at room temperature.
After ten minutes, l ml aliquots of a silicic acid/n-heptane
Suspension (10 g/l) were added and mixed thoroughly for 30
seconds. To absorb the phosphatidylcholine contaminating the
upper phase, again l ml aliquots of a SiO^w-heptane Suspension
(20 g/l) were added. It was necessary to mix the suspensions
continuously during pipetting. The Suspension was prepared
from precipitated dried silicic acid, with a particle size less than
0.1 mm. An additional heat activation of the silicic acid was
not necessary.
After ten minutes the samples were centrifuged for a few
seconds at 1000g and decanted into scintillation vials. 2ml n-
heptane were added to the two scintillation vials containing 0.1
ml radioactive Substrate solution. 8ml scintillation cocktail
(5.5 g PPO, 0.07 g POPOP, 667 ml xylene, 333 ml Triton X 100)
were added to each vial, mixed and measured in a liquid
scintillation counter.
The catalytic activity concentrations b of the samples were
calculated:
. counts/min (sample) — counts/min (blank) -b = ——— —. -: factor
Factor
counts/min (total activity)
600·10-3 1
= 208.3 U/l0.8-180 m i n - 2 0 - 10~61
l U = l micromol liberated palmitate per minute
The factor was composed of the auiount of Substrate added
per vial (600 nmol), the recovery indcx for the liberated fatty
acid (0.8) the incubation time (180 min and the sample volume
(0.02 ml).
Results
The kinetics of the reaction of phospholipase A2 are
shown in figure l for a blank sample (a), for the
control sample of purified phospholipase A2 (b) and
for sera of patients with acute pancreatitis (c—g).
The reaction shows a linear response over at least
180 minutes. In the blank sample, which was human
serum incubated after addition of some crystals of
Na2-EDTA to trap the calciumrions, we found only
a minimal pseudoactivity of 0.1 U/l originatiftg from
the spontaneous hydrolysis of phosphatidylcholine.
The spontaneous hydrolysis and radiolysis of phos-
phatidylcholine in EDTA-inhibited serum samples
was in the same ränge äs in the albumin blank (not
shown). This indicates that there is no additional
spontaneous hydrolysis in serum.
In a dilution experiment (fig. 2) we used purified hog
pancreas phospholipase A2 dissolved and diluted in
the serum of a healthy person (a). An ascites sample
of a patient with acute pancreatitis was diluted in
bovine serum albumin solution (b). The blank was
serum or albumin solution devoid of purified phos-
pholipase A2. We obtained linearity up to at least
30 U/l.
An optimal Substrate concentration was evaluated
using an ascites sample of a patient with severe acute
pancreatitis. Phospholipase A2 activity was measured
employing phosphatidylcholine concentrations rang-
ing from 0.1 to 12.5 mmol/1 in the assay mixture at
a constant ratio of unlabelled to labelled Substrate
(fig. 3, cürve a). Substrate concentrations higher than
12.5 mmol/1 were not employed due to solubility
Problems, and maximal velocity (Kmax) was not re-
ached at the highest experimental Substrate concen-
trations. As indicated in curve b, we found a maximal
yield between 3 and 8 mmol/1. At a Substrate concen-
tration of 5 mmol/1 optimal assay conditions were
reached with respect to accuracy and turnover of the
labelled Substrate.
The simplification of the extractioii procedure re-
sulted in an improvement of the fatty acid recovery
rate. It was almost twice äs high (79%), äs that
obtained using the original method of Shakir (49%).
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Fig. 1. Liberation of labelled palmitic acid monitored during
an incubation time of 210 minutes; the first blank value
was subtracted from all other values.
a) Blank sample of human serum and additional Na2-
EDTA.
b) Standard sample of hog pancreas phospholipase A2,
diluted l: 250 000 (vol/vql).
c—g) sera of patients with acute pancreatitis.
The two-step addition of the SiO2/n-heptane Suspen-
sion led to 80% extraction of the fatty adds from
the aqueous into the w-heptane phase, and a thorcmgh
adsorption of the träces of phosphatidylcholine was
achieved. Without the second Step, the Separation of
fatty acid and phosphatidylcholine was inadequate
(not shown). In the blank sample we found a spon-
taneous radiolysis and hydrolysis in the ränge of l %
to 1.5% of the employed Substrate.
The interassay and intraassay precision, obtained
with the control sample (diluted hog pancreas phos-
pholipase Ai) was below 10% and 5%, respectively
(tab. 1).
Tab. 1. Precision of the phospholipase A2 assay. The intraassay
variability was calculated from siiigle measuirements,
the interassay precision, from means of triplicates.
Precision
Interassay
Intraassay
n
6
10
Mean
(U/l)
9.1
10.2
SD
(U/l)
0.8
0.4
CV
(%)
8.8
4.1
60
50
„ 40
2
(M
o 30
l/l
l
20
10
1/2
Dilution
1/1
Fig. 2. Dilution of phospholipase A2-containing samples;
a) Purified phospholipase A2 from hog pancreas in a
stock solution (l: 125000), diluted in serum of a healthy
person.
b) Ascites sample of a patient with acute necrotizing
pancreatitis, diluted geometrically in bovine serum albu-
min solution.
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Fig. 3. Enzyme activity versus Substrate concentration (a).
The yield of the labelled palmitic acid with respect to
the labelled phosphatidylcholine
(counts/min (sample) — counts/min (blank)
counts/min (total activity)
plotted versus the phosphatidylcholine concentration
(b).
The synibols represent the means of triplicates of two
independent experiments.
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The mean phospholipase A2 activity of 30 serum
samples of a healthy control group was 0.66 ±0.11
U/l). A preliminary reference ränge up to 1.0 U/l was
suggested. In a control group of 20 patients with
gastrointestinal disease other than acute pancreatitis
we found similar activities below l U/l. In serum
samples of 50 patients with acute pancreatitis, cata-
lytic activity ranged from 0.5 U/l up to 20 U/l.
As a typical clinical example, figure 4 shows a follow-
up over l1 days of a 39 year-old male patient with
severe acute pancreatitis. The patient underwent ab-
dominal surgery because of extended pancreatic
necrosis. Endotracheal intubation was carried out
because of lung failure. Mechanical ventilatory sup-
port was given until day 9 after the onset of pain.
During the following days he needed an additional
oxygen supply. Serum samples were drawn every day
and lung function was monitored by blood gas analy-
sis. The pulmonary Situation of the patient is de-
scribed by the oxygenation index, which is the partial
arterial oxygen pressure (PaOa) divided by the inspired
fraction of oxygen (FiO2)· A low oxygenation index
indicates a bad lung function. It worsened twice dur-
ing hospitalization at days 4 and 10. At the same
times phospholipase A2 activities showed two impres-
300
l
2
t Cd]
Fig. 4. Follow up of a sample patient with severe acute pan-
creatitis. Day 0 is the onset of the disease
a) phospholipase A2-activity
b) pancreatic isoamylase activity
c) immunoreactive lipase
d) oxygenation index: partial arterial oxygen pressure
divided by the inspired fraction of oxygen (Pao2/Fio2)· °
sive peaks reaching about 10 U/l. In contrast, amylase
and lipase values were only moderately increased in
the beginning and normalized independently of the
clinical course. They were not correlated to phospho-
lipase A2 activities.
In intraoperatively drawn ascites samples of patients
with acute pancreatitis (n == 6*)9 elevated phospholi-
pase A2 activities between 1.6 U/l and 9.0 U/l were
measured. Ascites and pleural effusions of patients
with other diseases (n = 6) showed activities below
l U/l.
Discussion
The enzyme assay presented here is based on the
method of Shakir (8), who measured phospholipase
A2 activities in post heparin plasma of rats'and of
purified snake venom enzyme. He did not detect any
phospholipase A2 activity in rat serum samples, To
adapt this method for human serum, we had to mod-
ify the assay conditions.
Phospholipases A2 of different origins need quite
different reaction conditions for optimal catalytic ac-
tivities (13). Üsing the original assay we found only
minimal enzyme activities in human serum. The ra-
ther low Substrate concentration öf phosphatidylcho*
line (0.75 mmol/1) employed in the original assay was
far from optimal ränge. Furthermore, the extremely
high sample-reagent ratio of 2:1,3 led to high blank
values and reduced activities. Preliminary experl·
ments indicate that this effect was due to a high
concentration of serum protein. Therefore, we used
a reduced sample-reagent ratio of l: 5.
Also lipoprotein-bound phospholipids seem to be
prone to a degradation by phospholipase A2 (14). In
normal sera the phospholipid concentration is in the
ränge of 2 to 3 mmol/1, most of it (66 ± 9%) being
phosphatidylcholine (15). In lipaemic sera this con^
centration can be increased several fold. In tracer
assay Systems, where only the added labelled phos-
phatidylcholine is measured, unlabelled serum phos-
phatidylcholine may greatly redxice the calculated
enzyme activity, depending on the difference between
the believed and the actual phosphatidylcholine con-
centration. This effect is minimized by the high sub-
strate concentration and the high sample-reagent ra-
tio in this assay.
Our aim was to minimize the sample volumes,
without loss of test precision. Despite the low sample
volume of 0.02 ml used in this assay, the measüfed
signal was high enough to guarantee an inter- and
intraassay precision, wkieh fulfils the usual require-
ments for enzyme assays.
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Phosphatidylcholine forms multilamellar liposomes
in aqueous Solutions, which hamper phospholipase
A2 activity. Therefore detergents like cholate have
been introduced in the assay Systems for phospholi-
pase A2 to form and stabilize monomeric micelles.
The concentration of Na-deoxycholate (5 mmol/1) in
this enzyme assay is relatively high and provides a
Substrate solution, which is stable over several days
at room temperature. Therefore a rather long incuba-
tion period of 180 minutes could be used.
In enzyme assays using unlabelled Substrates, the
optimal reaction conditions are reached with sub-
strate Saturation and therefore maximal reaction ve-
locity. Here the optimum was reached at a lower
Substrate concentration. Curve b in figure 3 shows
the best yield of labelled palmitic acid. Other concen-
trations lead to a lowered yield and thus to dimin-
ished accuracy of the experiment. Measurements per-
formed when the concentrations of Substrate are too
low will therefore be subject to high inaccuracy.
For easier handling an enzyme assay should be per-
formed äs a "one pot reaction". This was achieved
by performing the incubation, extraction and washing
of the upper phase in the same vial, without any loss
in activity and without renewed contamination of
the upper phase by phosphatidylcholine. Only liquid
scintillation counting has to be performed in a separ-
ate scintillation vial. Using this simplified extraction
procedure, we wer e able to measure 70 samples within
the same series.
This method is strictly specific for the phospholipase
A2 activity. Phospholipase Aj activity and phospho-
lipase A!-like activity, for example that of lipase,
which can be elevated several fold in acute pancrea-
titis, do not influence this assay, because the fatty
acids are selectively labelled in position 2.
The measurable catalytic activity concentration of
phospholipase A2 has been increased several fold
compared to that achieved in the original method of
Shakir. In patients with acute pancreatitis, it was
increased up to 20 fold over the normal ränge, indi-
cating a high sensitivity. In the patient reported in this
paper, relatively low values for pancreatic isoamylase
and lipase are not correlated with a severe course of
acute pancreatitis, while elevated phospholipase A2
values do correlate with poor lung function; thus
phospholipase A2 seems to behave differently from
the other pancreatic enzymes.
The method described in this paper is easy to per-
form, has a good reproducibility and uses only com-
mercially available reagents. It therefore qualifies äs
a tool for further studies on phospholipase A2 and
its role in acute pancreatitis.
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